Influenza-B Paired Antibody
Greater than 90%.
Description
Product Specs
Exceeds 90% purity.
* Influenza-B coating antibody is also prepared in PBS with a pH of 7.4.
For storage durations of up to one month, maintain Influenza-B Paired Antibody at a temperature of 4°C. For extended storage, keep at -20°C. It is important to avoid repeated freeze-thaw cycles to maintain the stability of the antibody.
Suitable for use in lateral flow immunoassays.
Purified monoclonal IgG2b by protein A chromatography.
Product Science Overview
Influenza B viruses (IBVs) are a significant cause of respiratory illness in humans, contributing to annual epidemics. Unlike Influenza A, which has multiple subtypes and can cause pandemics, Influenza B has two main lineages: Victoria and Yamagata. Despite being less diverse, IBVs still pose a considerable health risk, especially to children and the elderly.
To study IBVs and develop effective treatments and vaccines, researchers often use mouse models. These models are crucial for preclinical trials of anti-influenza drugs and vaccines. A notable example is the development of a mouse-adapted IBV strain through serial passages in BALB/c mice. This adaptation process involves inducing specific amino acid substitutions in viral proteins, such as hemagglutinin (HA) and neuraminidase (NA), to enhance the virus’s ability to infect and replicate in mice .
Mouse anti-influenza B paired antibodies are generated by immunizing mice with IBV antigens. These antibodies are then harvested and purified for use in various applications, including diagnostic assays, therapeutic research, and vaccine development. The paired antibodies typically target different epitopes on the virus, providing a robust tool for detecting and neutralizing IBVs.
- Diagnostic Assays: Mouse anti-influenza B paired antibodies are used in diagnostic assays to detect the presence of IBVs in clinical samples. These assays are essential for early diagnosis and management of influenza infections.
- Therapeutic Research: Researchers use these antibodies to study the immune response to IBVs and to develop new antiviral therapies. For example, combining antibodies with antiviral drugs, such as zanamivir, has shown promising results in mouse models .
- Vaccine Development: The antibodies are also used to evaluate the efficacy of influenza vaccines. By assessing the immune response in vaccinated mice, researchers can determine the protective potential of candidate vaccines .
